Cannabinoids are the hot new ingredients for the medical community, and at the helm is cannabidiol or CBD. These chemicals are produced by the cannabis plant, and although there are over 100 of them, most of them are shrouded in mystery, save for cannabidiol and THC (delta-9 tetrahydrocannabinol).
THC is produced in higher levels by marijuana, and it creates the psychoactive high that cannabis is famous for.
Cannabidiol’s strength, on the other hand, lies in its medicinal properties. The chemical is said to be effective against a variety of conditions ranging from anxiety and high blood pressure to chronic pain and insomnia. Equally as versatile as hemp, CBD can be infused into almost anything once it’s extracted.
Results from a recent study could provide an even more effective way to invest CBD for maximum benefits. Bioavailability refers to the amount of a medicine or drug ingested that is absorbed into the body, and CBD is known to have poor oral bioavailability, mainly due to its poor aqueous solubility and extensive first-pass metabolism.
Most of the time when consumers use CBD oil, 90-95% of the CBD isn’t absorbed by the body, meaning you’ll have to spend more resources for higher doses if you want it to be effective.
The August 2019 study was published in the journal Molecules, and it sought to determine whether the absorption of CBD could be improved by using a more effective delivery system. A novel self-emulsifying drug delivery system (SEDDS) based on VESIsorb® formulation technology was used to suspend the CBD molecules (SEDDS-CBD). This formulation was tested against CBD diluted with medium-chain triglycerides (MCT-CBD).
Researchers administered the CBD to 16 healthy volunteers (eight men and eight women) in a randomized, double-blind cross-over study. This means the test subjects were given one formulation on one day then switched to the other formulation after a 14-day break.
They found out that a single oral administration of the SEDDS-CBD CBD led to 4.4-fold higher blood plasma levels of CBD compared to the control CBD formula, and that faster absorption occurred with SEDDS-CBD CBD compared to the control formulation. Normally, women absorb cannabidiol more effectively than men, but the SEDDS-CBD reduced the gender difference by a wide margin.
The researchers surmised that: “SEDDS-CBD based on VESIsorb® technology offers a novel, good, tolerable, and effective oral cannabinoid delivery system. CBD has a number of potential health benefits, however, our data demonstrated that unless the SEDDS formulation is used, there is relatively poor bioavailability of the standard CBD formulations (such as MCT oil) and could lead to diminished or no benefits for this natural product.”
It would be enlightening to see how cannabidiol companies like MCTC Holdings Inc. (OTC: MCTC) plan to use the findings of this research in their bid to serve customers better.
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire is part of the InvestorBrandNetwork.